Literature DB >> 21472730

Solid-state characterization of novel active pharmaceutical ingredients: cocrystal of a salbutamol hemiadipate salt with adipic acid (2:1:1) and salbutamol hemisuccinate salt.

Krzysztof J Paluch1, Lidia Tajber1, Curtis J Elcoate2, Owen I Corrigan1, Simon E Lawrence2, Anne Marie Healy3.   

Abstract

The production of salt or cocrystalline forms is a common approach to alter the physicochemical properties of pharmaceutical compounds. The goal of this work was to evaluate the impact of anion choice (succinate, adipate, and sulfate) on the physicochemical characteristics of salbutamol forms. Novel crystals of salbutamol were produced by solvent evaporation: a cocrystal of salbutamol hemiadipate with adipic acid (salbutamol adipate, SA), salbutamol hemisuccinate tetramethanolate (SSU.MeOH), and its desolvated form (SSU). The crystalline materials obtained were characterized using thermal, X-ray, nuclear magnetic resonance, Fourier transform infrared spectroscopy, dynamic vapor sorption (DVS), and elemental analysis. The crystal forms of SA and SSU.MeOH were determined to be triclinic, (Pī), and monoclinic, (P2(1) /n), respectively. DVS analysis confirmed that SSU and SA do not undergo hydration under increased relative humidity. Both thermal and elemental analyses confirmed the stoichiometry of the salt forms. The aqueous solubilities of SA and SSU were measured to be 82 ± 2 mg/mL (pH 4.5 ± 0.1) and 334 ± 13 mg/mL (pH 6.6 ± 0.1), respectively. Measured values corresponded well with the calculated pH solubility profiles. The intrinsic dissolution rate of cocrystallized SA was approximately four times lower than that of SSU, suggesting its use as an alternative to more rapidly dissolving salbutamol sulfate.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472730     DOI: 10.1002/jps.22569

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Molecular structure studies of (1S,2S)-2-benzyl-2,3-dihydro-2-(1H-inden-2-yl)-1H-inden-1-ol.

Authors:  Tao Zhang; Krzysztof Paluch; Gaia Scalabrino; Neil Frankish; Anne-Marie Healy; Helen Sheridan
Journal:  J Mol Struct       Date:  2015-03-05       Impact factor: 3.196

2.  Crystal structure of rac-4-[2-(tert-butyl-aza-nium-yl)-1-hy-droxy-eth-yl]-2-(hy-droxy-meth-yl)phenol benzoate.

Authors:  Wenju Liu; Qiliang Chen; Linda Yu
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-08-11

3.  Improving the solubility and bioavailability of anti-hepatitis B drug PEC via PEC-fumaric acid cocrystal.

Authors:  Long Li; Xian-Hong Yin; Kai-Sheng Diao
Journal:  RSC Adv       Date:  2020-10-02       Impact factor: 4.036

4.  Combining X-ray and NMR Crystallography to Explore the Crystallographic Disorder in Salbutamol Oxalate.

Authors:  Aneesa J Al-Ani; Patrick M J Szell; Zainab Rehman; Helen Blade; Helen P Wheatcroft; Leslie P Hughes; Steven P Brown; Chick C Wilson
Journal:  Cryst Growth Des       Date:  2022-07-20       Impact factor: 4.010

5.  Acemetacin cocrystals and salts: structure solution from powder X-ray data and form selection of the piperazine salt.

Authors:  Palash Sanphui; Geetha Bolla; Ashwini Nangia; Vladimir Chernyshev
Journal:  IUCrJ       Date:  2014-02-28       Impact factor: 4.769

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.